Helsinki - Free Realtime Quote EUR

Biohit Oyj (BIOBV.HE)

Compare
2.9700
-0.0200
(-0.67%)
As of 10:36:59 AM GMT+2. Market Open.
Loading Chart for BIOBV.HE
DELL
  • Previous Close 2.9900
  • Open 2.9600
  • Bid 2.9600 x --
  • Ask 2.9700 x --
  • Day's Range 2.9600 - 2.9700
  • 52 Week Range 1.8000 - 4.3500
  • Volume 620
  • Avg. Volume 28,998
  • Market Cap (intraday) 45.089M
  • Beta (5Y Monthly) 0.76
  • PE Ratio (TTM) 27.00
  • EPS (TTM) 0.1100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Apr 15, 2014
  • 1y Target Est 3.20

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; Biohit Active B12, a test for measuring the levels of active vitamin B12; BIOHIT Total 25OH Vitamin D, a test for determination of vitamin D status; and Biohit Calprotectin test for measuring human calprotectin. It also offers GastroPanel quick test NT, a quantitative immunochromatographic test for the detection of Helicobacter pylori (H. Pylori) and atrophic gastritis; BIOHIT Celiac Quick test for diagnosis of celiac disease; Biohit ColonView Quick test, a test for detection of fecal occult blood; Biohit Helicobacter Pylori UFT300 and Helicobacter Pylori Quick test methods to detect H. pylori infection; and Lactose Intolerance quick test to support the diagnosis of lactose intolerance in a duodenal biopsy specimen. In addition, the company provides acetaldehyde-binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenge, which helps in quitting smoking; and monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.

www.biohithealthcare.com

47

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIOBV.HE

View More

Performance Overview: BIOBV.HE

Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

BIOBV.HE
29.69%
OMX Helsinki_PI
0.00%

1-Year Return

BIOBV.HE
57.14%
OMX Helsinki_PI
0.00%

3-Year Return

BIOBV.HE
68.75%
OMX Helsinki_PI
0.00%

5-Year Return

BIOBV.HE
22.25%
OMX Helsinki_PI
0.00%

Compare To: BIOBV.HE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIOBV.HE

View More

Valuation Measures

Annual
As of 1/30/2025
  • Market Cap

    45.39M

  • Enterprise Value

    41.09M

  • Trailing P/E

    27.18

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.24

  • Price/Book (mrq)

    4.20

  • Enterprise Value/Revenue

    2.94

  • Enterprise Value/EBITDA

    22.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.81%

  • Return on Assets (ttm)

    8.08%

  • Return on Equity (ttm)

    16.68%

  • Revenue (ttm)

    13.98M

  • Net Income Avi to Common (ttm)

    1.65M

  • Diluted EPS (ttm)

    0.1100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5M

  • Total Debt/Equity (mrq)

    6.48%

  • Levered Free Cash Flow (ttm)

    -796.88k

Research Analysis: BIOBV.HE

View More

Company Insights: BIOBV.HE

Research Reports: BIOBV.HE

View More

People Also Watch